All In Biotech

Drug Trial Radar · NCT04586244

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy

Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

30

Actual

Start

Jan 14, 2022

Primary completion

Jan 29, 2024

Study completion Jan 29, 2024

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.

Conditions

  • Urothelial Carcinoma

Interventions

  • retifanlimabDrug

    retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,

  • epacadostatDrug

    epacadostat will be administered daily twice daily orally up to and including day of surgery.

  • INCAGN02385Drug

    INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.

  • INCAGN02390Drug

    INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in CD8+ Lymphocytes Within the Resected TumorTime frame: up to 69 days

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Iowa

    Iowa City, Iowa

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio State University Medical Center Division of H

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Hopital Europeen Georges Pompidou (Hegp)

    Paris, France

  • Hospital Saint Louis

    Paris, France

  • Institut Gustave Roussy

    Villejuif, France

  • Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari

    Bari, Italy

  • L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi

    Bologna, Italy

  • Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele

    Milan, Italy

  • Universita Campus Bio Medico Di Roma

    Roma, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)

    Verona, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.